Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Study: Screen Hospitalized Lupus Patients for Venous Thromboembolism

Catherine Kolonko  |  Issue: September 2019  |  September 17, 2019

Kateryna Kon / shutterstock.com

Kateryna Kon / shutterstock.com

When patients with lupus are hospitalized, they should be screened and likely treated for venous thromboembolism, researchers of a nationwide study say.

In May, ACR Open Rheumatology published results of the large retrospective study spanning several years. Researchers analyzed trends in mortality, morbidity and hospitalization from venous thrombo­embolism (VTE), specifically among patients diagnosed with systemic lupus erythematosus (SLE). The results showed hospitalized lupus patients with thrombo­embolism had more than two times the risk of dying as those without VTE, and thrombo­­embolism was identified as an independent risk factor for mortality in these patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The findings underline the importance of proper screening and implementation of prophylactic anticoagulation for this patient population, says study author Shweta Kishore, MD, an assistant professor in the Division of Rheumatology at the University of Missis­sippi Medical Center (UMMC), Jackson.

Venous thromboembolism is the third leading vascular diagnosis after heart attack and stroke, according to the American Heart Association. Previous cohort studies have demonstrated the risk of VTE is higher among patients who have lupus, especially in people with antiphospholipid antibodies that increase the risk of excessive blood clotting, according to the authors. This study sought to address a lack of data on how these patients fare during and after hospital stays.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“What we wanted to see is [whether] this affects their mortality [and] other hospital outcomes, such as the cost of hospitalization, the length of stay and their disability status at the time of discharge,” Dr. Kishore says.

The Study

Researchers reviewed the Nationwide Inpatient Sample (NIS) database from 2003–2011 to track the study’s primary endpoints of inpatient mortality, hospitalization trends and inpatient mortality rate. They also identified secondary outcomes of hospital length of stay and cost, as well as level of disability at discharge.

Patients were included in the study if they were 18 or older and had a diagnosis of SLE and VTE. Only patients with VTE as one of the top three discharge diagnoses were included in the cohort, while those with superficial thrombosis were excluded. Out of nearly 300,000 patients in the study who were hospitalized with SLE, 9,175 (3.06%) also had VTE and, compared with patients without VTE, suffered significantly higher inpatient mortality at a rate of 5% vs. 2.0% (odds ratio [OR] of 2.35 [95% confidence interval (CI) 2.10–2.62]; P<0.001). The same group also had greater disability at discharge (34% vs. 26%; OR of 1.53 [95% CI 1.46–1.62]; P<0.001) after longer, costlier hospital stays.

“Our study is the largest retrospective analy­sis of a national discharge database” to study this population, says Dr. Kishore. “What we found in our study is that the patients who had a discharge diagnosis of thrombo­embolism had a much higher inpatient mortality rate as compared to the patients who did not have venous thromboembolism. They had a greater [level of] disability at discharge. Their hospitalization cost was higher by $25,000 for each hospitalization, and they stayed in the hospital longer by 3.57 days.”

Additional analysis of the database indicates that being African American was associated with increased risk of VTE, as was being male and younger, possibly because men with lupus tend to have severe forms of the disease, according to the authors.

The study’s senior author, Vikas Majithia, MD, MPH, a UMMC professor of medicine and chief and fellowship program director of rheumatology, says it was interesting that there were no differences between urban and rural hospitals.

“In this sample, there was no difference, and the same was true whether these patients were admitted to a teaching or non-teaching hospital,” he says. “This study did not show disparity [by] geography or teaching status of the hospitals. But that does not mean that it doesn’t exist.”

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:mortality riskvenous thromboembolism

Related Articles

    Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

    October 7, 2020

    An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

    Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

    Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

    August 16, 2018

    Antiphospholipid syndrome (APS) is an autoimmune clotting disorder that may present catastrophically with multiple thromboses over a short period of time. In this article, we examine the case of a woman with undiagnosed APS whose first symptoms presented during a long-haul flight. A review of the literature on thrombosis at high altitudes and during long…

    Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

    December 1, 2022

    PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

    Rheumatology Case Report: Deep Vein Thrombosis Detected by Point-of-Care Ultrasound

    April 18, 2017

    Case A 46-year-old Caucasian female presented to the outpatient rheumatology clinic where she had been followed for several years. Her chief complaint was pain in her right knee, posterior right thigh and right hip that had begun gradually over the previous three weeks. Her past medical history was significant for rheumatoid arthritis (RA), obesity and…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences